HQH vs REPL Comparison

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.